title: Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats.
abstract: Lipid metabolic disorders are widely considered to be one of the most critical and basic link in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). The aim of this study was to illustrate the alleviation function of resveratrol (Res) on NAFLD and the roles of hepatic fatty acid synthase (FAS), low density lipoprotein receptor (LDLr), scavenger receptor class B type I (SR-BI), and thyroid hormone receptor β1 (TRβ1), which are the key molecules involved in lipid metabolism. Adult male Wistar rats were fed a normal diet or high fat/sucrose diet (HFS) with or without resveratrol for 13 weeks. HFS induced NAFLD formation and increased the lipids concentrations in serum and livers of rats, while noticeable improvement has been reached by Res intervention. Moreover, Res protected against HFS-induced decrease in hepatic LDLr and SR-BI mRNA and protein expressions, whereas TRβ1 expressions were impervious with/without Res. Unexpectedly, hepatic FAS gene expressions were markedly diminished in NAFLD rats and were gradually increased by treatment with Res. These data indicate that the alleviative effects of Res on NAFLD are associated with up regulation of hepatic LDLr and SR-BI gene expressions, which provide new insights into the pharmacological targets of Res in the prevention of NAFLD.
authors.affiliation: Department of Nutrition and Food Hygiene, School of Public Health, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, PR China.
authors.forename: Peng
authors.initials: P
authors.lastname: Xin
authors.forename: Hao
authors.initials: H
authors.lastname: Han
authors.forename: Danhong
authors.initials: D
authors.lastname: Gao
authors.forename: Wei
authors.initials: W
authors.lastname: Cui
authors.forename: Xuefeng
authors.initials: X
authors.lastname: Yang
authors.forename: Chenjiang
authors.initials: C
authors.lastname: Ying
authors.forename: Xiufa
authors.initials: X
authors.lastname: Sun
authors.forename: Liping
authors.initials: L
authors.lastname: Hao
mesh_terms: D000818:Animals; D004734:Energy Metabolism / Q000187:drug effects; D005234:Fatty Liver / Q000178:diet therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D015870:Gene Expression / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease; D051381:Rats; D017208:Rats, Wistar; D011973:Receptors, LDL / Q000235:genetics*; D000077185:Resveratrol; D051122:Scavenger Receptors, Class B / Q000235:genetics*; D013267:Stilbenes / Q000494:pharmacology*; D037042:Thyroid Hormone Receptors beta / Q000235:genetics; D015430:Weight Gain / Q000187:drug effects; D019014:fas Receptor / Q000235:genetics
chemical_list: C491898:Fas protein, rat; D011973:Receptors, LDL; C495125:Scarb1 protein, rat; D051122:Scavenger Receptors, Class B; D013267:Stilbenes; D037042:Thyroid Hormone Receptors beta; D019014:fas Receptor; D000077185:Resveratrol